BCMA Test Your Knowledge

Test Your Knowledge

Quiz: How Do Patients With MM Who Received Anti-BCMA Therapy Respond to COVID-19 Vaccinations?

12/01/2021

True or false: Patients with MM who received anti-BCMA antibody-based therapy were associated with having a lack of T-cell responses following SARS-CoV-2 vaccination.

True or false: Patients with MM...

12/01/2021

Oncology

Quiz

Quiz: Which of the Following Inhibitors Target BCMA in MM?

11/10/2021

Which of the following inhibitors showed an increase in BCMA surface density and a decrease in soluble BCMA levels?

Which of the following...

11/10/2021

Oncology

Test Your Knowledge

Quiz: Is Extramedullary Disease Associated with Poor Prognoses in R/R MM?

11/02/2021

True or false: In R/R MM, extramedullary disease is linked to significantly poor prognoses.

True or false: In R/R MM,...

11/02/2021

Oncology

Quiz

Quiz: Can Anti-BCMA CAR-T Cell Therapy Cause Humoral Immune Deficiencies in R/R MM?

10/14/2021

True or false: A profound and lasting humoral immune deficiency was found after anti-BCMA CAR-T cell therapy in patients with R/R MM.

True or false: A profound and...

10/14/2021

Oncology

Test Your Knowledge

Quiz: Which Cell Type is Known for BCMA Expression?

09/20/2021

Which of the following cell type is known for BCMA expression?

Which of the following cell type...

09/20/2021

Oncology

Test Your Knowledge

Quiz: Responses to BCMA-Directed CAR-T Therapy for R/R MM

09/07/2021

True or false: Results from the CARTITUDE-1 trial showed that BCMA-directed CAR-T therapy yielded early, deep, and durable responses in patients with R/R MM.

True or false: Results from the...

09/07/2021

Oncology

Test Your Knowledge

Quiz: Does Teclistamab Therapy Display Promise in BCMA-Positive MM?

11/19/2020

True or False: Data suggest that teclistamab is a promising therapy for patients with BCMA-positive MM.

True or False: Data suggest that...

11/19/2020

Oncology

Test Your Knowledge

Quiz: The Basics of BCMA Expression in Multiple Myeloma

10/08/2020

True or False: BCMA is expressed in nearly all MM tumor cells and serves as a potential biomarker for identifying malignant plasma cells in this patient population.

True or False: BCMA is expressed...

10/08/2020

Oncology

Test Your Knowledge

Quiz: Promising Role of BCMA-Directed CAR-T Therapy for R/R MM

09/25/2020

True or False: According to data from the CARTITUDE-1 trial, the BCMA-directed CAR-T therapy JNJ‑4528 was very effective and yielded 100% overall response rate in patients with relapsed or refractory MM.

True or False: According to data...

09/25/2020

Oncology

Test Your Knowledge

Quiz: Can BCMA-Targeting CAR T-Cells Improve Patient Outcomes in MM?

08/26/2020

True or False: Multiple studies have demonstrated positive results with BCMA-targeting CAR T-cells for the treatment of relapsed and refractory MM.

True or False: Multiple studies...

08/26/2020

Oncology

Recent News

News

NCCN Recommends Rusfertide as Category 1 Option Across Low- and High-Risk Polycythemia Vera

09/22/2026

Stephanie Holland

Updated NCCN Guidelines recommend rusfertide as a Category 1 treatment option across low- and high-risk polycythemia vera, incorporating the first-in-class hepcidin mimetic into clinical management following findings demonstrating hematocrit...

Updated NCCN Guidelines...

09/22/2026

Oncology

News

FDA Grants Fast Track Designation to LYT-200 Plus Hypomethylating Therapy for Relapsed or Refractory High-Risk Myelodysplastic Syndromes

09/22/2026

Emily Estrada

The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...

The FDA granted Fast Track...

09/22/2026

Oncology

News

Trastuzumab Deruxtecan Reduces Risk of Progression or Death in First-Line HER2-Mutant Non-Small Cell Lung Cancer

09/22/2026

Stephanie Holland

Results from the phase 3 DESTINY-Lung04 trial demonstrated that first-line trastuzumab deruxtecan significantly improved progression-free survival and response compared with pembrolizumab plus chemotherapy in advanced HER2-mutant non-small...

Results from the phase 3...

09/22/2026

Oncology

News

Tafasitamab Plus Lenalidomide and R-CHOP Significantly Improves PFS in High-Risk Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma

09/21/2026

Emily Estrada

Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...

Results from the phase 3...

09/21/2026

Oncology

FDA Approval

FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer

09/18/2026

Stephanie Holland

Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...

Based on results from the phase...

09/18/2026

Oncology

FDA Alerts

FDA Approves Taletrectinib Label Update Reflecting Durable Responses in TKI-Naïve ROS1-Positive Non-Small Cell Lung Cancer

09/17/2026

Emily Estrada

The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...

The FDA approved a supplemental...

09/17/2026

Oncology

News

Epcoritamab Plus Lenalidomide and Rituximab Shows Superior Efficacy in Second-Line or Later Follicular Lymphoma

09/17/2026

Emily Estrada

Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...

Results from the phase 3 EPCORE...

09/17/2026

Oncology

News

Low-Dose Ruxolitinib Significantly Reduces Acute Graft-Versus-Host Disease After Haploidentical Transplantation

09/17/2026

Emily Estrada

Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...

Results from a phase 3 trial...

09/17/2026

Oncology

News

Sacituzumab Govitecan Plus Pembrolizumab Fails to Significantly Improve PFS in PD-L1–High Metastatic Non-Small Cell Lung Cancer

09/16/2026

Stephanie Holland

Results from the phase 3 EVOKE-03 trial demonstrated that adding sacituzumab govitecan to pembrolizumab did not significantly improve progression-free or overall survival in untreated patients with PD-L1–high metastatic non-small cell lung...

Results from the phase 3...

09/16/2026

Oncology

FDA Alerts

FDA Label Update Shortens Initial Tarlatamab Monitoring to Support Broader Extensive-Stage Small Cell Lung Cancer Treatment Access

09/16/2026

Stephanie Holland

The FDA updated the prescribing information for tarlatamab to substantially shorten monitoring following the first 2 doses in patients with extensive-stage small cell lung cancer, potentially reducing treatment burden and facilitating...

The FDA updated the prescribing...

09/16/2026

Oncology